STOK
NASDAQ · Biotechnology
Stoke Therapeutics Inc
$33.40
-0.11 (-0.33%)
Open$33.61
Previous Close$33.51
Day High$35.29
Day Low$33.37
52W High$39.81
52W Low$5.35
Volume—
Avg Volume723.7K
Market Cap1.98B
P/E Ratio48.21
EPS$0.67
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+50.2% upside
Current
$33.40
$33.40
Target
$50.17
$50.17
$29.72
$50.17 avg
$68.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 40.15M | 323.22M | 315.22M |
| Net Income | -97,739,275 | -37,471,003 | -43,595,472 |
| Profit Margin | -243.4% | -11.6% | -13.8% |
| EBITDA | -109,230,685 | -52,091,948 | -53,358,586 |
| Free Cash Flow | — | -52,998,459 | -42,607,892 |
| Rev Growth | — | +14.4% | -1.8% |
| Debt/Equity | — | 0.58 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |